Tema Etfs LLC Sells 5,092 Shares of Edwards Lifesciences Corporation $EW

Key Points

• Tema Etfs LLC reduced its holdings in Edwards Lifesciences Corporation by 23.5%, selling 5,092 shares, which left them with 16,543 shares valued at approximately $1.2 million.
• Despite the sale, several institutional investors have raised their stakes in Edwards Lifesciences, with total institutional ownership at 79.46%.
• Edwards Lifesciences reported better-than-expected earnings, with $0.67 EPS for the quarter, surpassing the consensus estimate of $0.62, alongside revenue of $1.53 billion.

Tema Etfs LLC trimmed its position in Edwards Lifesciences Corporation (NYSE:EW - Free Report) by 23.5% during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 16,543 shares of the medical research company's stock after selling 5,092 shares during the quarter. Tema Etfs LLC's holdings in Edwards Lifesciences were worth $1,199,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Jennison Associates LLC grew its holdings in Edwards Lifesciences by 34.3% in the 1st quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company's stock valued at $731,036,000 after buying an additional 2,576,383 shares in the last quarter. Brown Advisory Inc. grew its holdings in Edwards Lifesciences by 7.6% in the 4th quarter. Brown Advisory Inc. now owns 8,155,355 shares of the medical research company's stock valued at $603,741,000 after buying an additional 575,699 shares in the last quarter. Deutsche Bank AG grew its holdings in Edwards Lifesciences by 10.4% in the 4th quarter. Deutsche Bank AG now owns 6,903,202 shares of the medical research company's stock valued at $511,044,000 after buying an additional 652,923 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its holdings in Edwards Lifesciences by 8.5% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 6,519,257 shares of the medical research company's stock valued at $482,621,000 after buying an additional 513,468 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Edwards Lifesciences by 21.8% in the 4th quarter. Northern Trust Corp now owns 6,505,227 shares of the medical research company's stock valued at $481,582,000 after buying an additional 1,165,845 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

EW has been the topic of several analyst reports. JPMorgan Chase & Co. increased their target price on Edwards Lifesciences from $80.00 to $85.00 and gave the stock a "neutral" rating in a report on Friday, July 25th. Morgan Stanley increased their target price on Edwards Lifesciences from $75.00 to $81.00 and gave the stock an "equal weight" rating in a report on Tuesday, July 15th. Piper Sandler increased their target price on Edwards Lifesciences from $83.00 to $90.00 and gave the stock an "overweight" rating in a report on Friday, July 25th. Argus raised Edwards Lifesciences to a "strong-buy" rating in a report on Thursday, July 10th. Finally, William Blair raised Edwards Lifesciences to a "strong-buy" rating in a report on Friday, July 25th. Three research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Edwards Lifesciences has a consensus rating of "Moderate Buy" and an average price target of $85.90.

Edwards Lifesciences Price Performance

Edwards Lifesciences stock traded up $0.25 during midday trading on Monday, reaching $81.48. The company's stock had a trading volume of 2,743,784 shares, compared to its average volume of 3,802,425. The business has a 50-day moving average price of $78.31 and a 200-day moving average price of $75.01. Edwards Lifesciences Corporation has a 52 week low of $64.00 and a 52 week high of $83.00. The stock has a market cap of $47.84 billion, a PE ratio of 11.72, a price-to-earnings-growth ratio of 3.92 and a beta of 1.07. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW - Get Free Report) last announced its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 EPS for the quarter, beating analysts' consensus estimates of $0.62 by $0.05. The firm had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The business's revenue for the quarter was up 11.9% on a year-over-year basis. During the same period last year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. On average, sell-side analysts predict that Edwards Lifesciences Corporation will post 2.45 EPS for the current year.

Insider Buying and Selling

In other Edwards Lifesciences news, insider Larry L. Wood sold 8,950 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, June 16th. The stock was sold at an average price of $75.23, for a total value of $673,308.50. Following the completion of the sale, the insider directly owned 206,900 shares in the company, valued at approximately $15,565,087. The trade was a 4.15% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, VP Daniel J. Lippis sold 4,114 shares of Edwards Lifesciences stock in a transaction that occurred on Monday, July 28th. The stock was sold at an average price of $79.46, for a total value of $326,898.44. Following the completion of the sale, the vice president owned 22,002 shares of the company's stock, valued at approximately $1,748,278.92. The trade was a 15.75% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 22,014 shares of company stock worth $1,698,844. 0.34% of the stock is owned by insiders.

About Edwards Lifesciences

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.